Clinical Trial Update: Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial in Japanese subjects comparing two formulations of biphasic insulin aspart 50 to assess bioequivalence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 50 (insulin aspart, biphasic 50/50)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED